
Quarterly report 2026-Q1
added 05-05-2026
Masimo Corporation Financial Ratios 2011-2026 | MASI
Annual Financial Ratios Masimo Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-29.4 | 83.7 | 65.6 | 50.0 | - | 45.7 | 32.9 | 38.8 | 22.6 | 19.4 | - | 29.5 | 19.4 | 22.8 |
P/S |
4.3 | 3.3 | 4.6 | 10.5 | - | 9.6 | 7.4 | 6.1 | 3.0 | 2.4 | - | 3.2 | 2.4 | 4.1 |
EPS |
-5.7 | 1.5 | 2.7 | 4.4 | - | 3.7 | 3.7 | 2.4 | 6.3 | 1.3 | - | 1.0 | 1.1 | 1.1 |
EV (Enterprise Value) |
10.4 B | 8.33 B | 11.1 B | 11.7 B | - | 8.62 B | 6.01 B | 4.71 B | 1.9 B | 1.53 B | - | 1.74 B | 1.24 B | 1.63 B |
EBITDA per Share |
-3.07 | 4.45 | 6.46 | 5.21 | - | 4.58 | 4.38 | 3.96 | 2.65 | 2.13 | - | 1.61 | 1.65 | 1.92 |
EV/EBITDA |
40.8 | - | 34.7 | 25.4 | 22.2 | 14.2 | 12.0 | - | 17.9 | 12.0 | 14.1 | |||
PEG |
- | - | -58.7 | 0.62 | -0.65 | 1.0 | 0.68 | - | -5.9 | 14.29 | 0.55 | |||
P/B |
8.5 | 5.0 | 7.0 | 8.5 | - | 7.7 | 6.6 | 6.7 | 6.8 | 4.6 | - | 5.3 | 4.4 | 7.4 |
P/CF |
45.6 | 72.4 | 320.4 | 57.0 | - | 60.1 | 29.4 | 521.2 | 30.0 | 84.6 | - | 41.8 | 19.8 | 33.9 |
ROE % |
-28.99 | 5.97 | 10.72 | 17.07 | - | 16.80 | 19.97 | 17.24 | 30.25 | 23.70 | - | 17.89 | 22.81 | 32.29 |
ROA % |
-11.61 | 2.68 | 4.47 | 14.03 | - | 14.05 | 16.76 | 13.78 | 13.84 | 12.83 | - | 13.31 | 16.63 | 23.69 |
ROCE % |
-25.35 | 10.00 | 15.68 | 18.17 | - | 18.07 | 20.63 | 23.69 | 25.63 | 23.47 | - | 23.80 | 29.87 | 44.25 |
Current Ratio |
1.7 | 1.8 | 1.7 | 5.6 | - | 5.8 | 5.4 | 4.3 | 2.3 | 2.4 | - | 2.6 | 2.5 | 3.1 |
DSO |
- | - | 12.7 | 22.6 | - | 64.9 | 51.0 | 59.6 | 51.3 | 48.9 | - | 56.1 | 55.5 | 55.6 |
DIO |
168.1 | 182.7 | 133.9 | 98.4 | - | 137.0 | 122.0 | 125.6 | 102.9 | 129.9 | - | 110.0 | 103.6 | 137.1 |
DPO |
84.4 | 92.3 | 63.7 | 29.2 | - | 64.5 | 52.0 | 46.0 | 42.9 | 70.9 | - | 54.2 | 59.0 | 67.6 |
Operating Cycle |
168.1 | 182.7 | 146.6 | 120.9 | - | 202.0 | 173.0 | 185.2 | 154.1 | 178.8 | - | 166.1 | 159.1 | 192.7 |
Cash Conversion Cycle |
83.7 | 90.5 | 82.9 | 91.7 | - | 137.4 | 121.0 | 139.2 | 111.2 | 107.9 | - | 111.9 | 100.1 | 125.0 |
All numbers in USD currency
Quarterly Financial Ratios Masimo Corporation
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.1 | - | -1.86 | 0.95 | -3.17 | - | 0.19 | 0.3 | 0.36 | - | 0.3 | 0.4 | 1.23 | - | 0.34 | 0.84 | 1.28 | 1.05 | 0.91 | 0.97 | - | 0.9 | 1.02 | 1.2 | 0.99 | 0.92 | 0.84 | 0.93 | 0.88 | 1.09 | 0.84 | 0.88 | -0.15 | 0.69 | 0.87 | 1.02 | 4.31 | 0.56 | 0.61 | 0.56 | 0.4 | 0.38 | 0.38 | 0.39 | - | 0.28 | 0.25 | 0.4 | 0.16 | 0.28 | 0.3 | 0.29 | 0.26 | 0.24 | 0.31 | 0.27 | 0.23 | 0.25 | 0.28 | 0.3 |
EBITDA per Share |
1.64 | - | 1.66 | 1.31 | 1.6 | - | 0.86 | 0.94 | 1.19 | - | 0.76 | 1.22 | 1.47 | - | 0.63 | 1.24 | 1.17 | 1.34 | 1.34 | 1.34 | - | 1.47 | 1.38 | 1.4 | 1.15 | 1.29 | 1.19 | 1.15 | 1.02 | 1.23 | 1.2 | 1.14 | 0.87 | 1.1 | 1.03 | 1.12 | 6.01 | 0.99 | 0.9 | 0.84 | 0.62 | 0.78 | 0.69 | 0.59 | - | 0.59 | 0.44 | 0.59 | 0.22 | 0.52 | 0.51 | 0.45 | 0.39 | 0.43 | 0.47 | 0.41 | 0.34 | 0.41 | 0.43 | 0.46 |
ROE % |
-12.63 | -25.51 | -24.84 | -11.78 | -15.53 | 3.22 | 4.42 | 4.95 | 5.39 | 7.90 | 9.40 | 9.71 | 11.05 | 9.47 | 13.41 | 15.51 | 16.58 | 15.06 | 14.61 | 15.15 | 12.78 | 17.31 | 18.03 | 17.72 | 16.80 | 17.11 | 18.80 | 19.49 | 19.97 | 14.06 | 13.12 | 14.83 | 17.24 | 56.73 | 56.74 | 55.86 | 53.67 | 6950.23 | 6952.45 | 6953.91 | 6955.33 | 25.59 | 23.67 | 4336.91 | 10724.09 | 10726.94 | 10726.47 | 6411.62 | 17.88 | 20.53 | 20.80 | 22.06 | 22.80 | 22.30 | 22.61 | 22.28 | 23.01 | 5.36 | 6.15 | 6.51 |
ROA % |
-5.44 | -10.83 | -10.83 | -5.31 | -6.81 | 1.28 | 1.80 | 1.68 | 3.81 | 4.77 | 5.38 | 3.35 | 5.79 | 7.18 | 10.45 | 12.82 | 13.72 | 12.48 | 12.09 | 12.52 | 10.66 | 14.46 | 15.09 | 14.89 | 14.05 | 14.33 | 15.76 | 16.34 | 16.76 | 11.84 | 10.85 | 12.04 | 13.78 | 40.87 | 40.30 | 38.97 | 36.64 | 3766.29 | 3766.25 | 3765.91 | 3766.12 | 13.02 | 12.47 | 2776.42 | 7704.51 | 7706.64 | 7707.40 | 4944.01 | 13.31 | 15.19 | 15.30 | 16.13 | 16.58 | 16.35 | 16.73 | 16.68 | 17.40 | 4.05 | 4.65 | 4.92 |
ROCE % |
36.64 | 24.75 | 27.36 | 19.65 | 16.52 | 9.56 | 11.80 | 11.43 | 11.23 | 10.88 | 12.72 | 12.31 | 13.23 | 10.22 | 14.83 | 17.67 | 18.84 | 18.45 | 18.06 | 18.01 | 14.35 | 19.62 | 19.83 | 19.65 | 18.94 | 19.23 | 19.83 | 20.71 | 21.47 | 22.08 | 23.01 | 23.74 | 25.38 | 74.61 | 75.20 | 75.64 | 75.11 | 30.37 | 34.29 | 37.60 | 39.39 | 36.60 | 34.01 | 29.96 | 22.17 | 26.04 | 24.53 | 25.87 | 24.42 | 28.70 | 28.92 | 30.12 | 31.21 | 30.30 | 30.57 | 30.26 | 31.25 | 6.84 | 7.99 | 9.17 |
Current Ratio |
1.9 | 1.7 | 1.8 | 1.8 | 1.7 | 1.7 | - | - | 1.9 | 1.8 | 1.8 | - | 1.7 | - | 1.7 | 5.8 | 5.6 | 5.9 | 5.8 | 5.9 | - | 5.7 | 5.6 | 6.7 | 6.1 | 6.1 | 6.1 | 6.1 | 6.2 | 6.2 | 6.2 | 6.2 | 5.0 | 5.0 | 5.0 | 5.0 | 3.1 | 3.1 | 3.1 | 3.1 | 2.2 | 1.9 | 1.9 | 2.3 | - | 2.1 | 2.8 | 4.4 | 3.9 | 3.9 | 3.9 | 3.9 | 3.8 | 3.8 | 3.8 | 3.8 | 4.2 | 4.2 | 4.2 | 4.2 |
DSO |
58.2 | - | - | - | - | - | - | - | 92.2 | - | - | - | 62.1 | - | 44.6 | 51.2 | 51.4 | 55.0 | 46.9 | 20.5 | - | 53.4 | 50.3 | 48.3 | 48.5 | 52.4 | 52.6 | 47.7 | 43.1 | 45.6 | 47.3 | 48.9 | 52.0 | 55.9 | 56.2 | 51.1 | 48.8 | 53.4 | 53.7 | 46.0 | 41.3 | 44.6 | 41.6 | 20.1 | - | 47.0 | 48.4 | 49.2 | 47.1 | 51.0 | 51.0 | 48.5 | 45.2 | 50.2 | 50.5 | 47.8 | 46.3 | 50.0 | 47.5 | - |
DIO |
233.0 | - | 212.8 | 205.5 | 197.1 | - | - | - | 360.6 | - | - | - | - | - | 98.5 | 197.0 | - | 179.8 | 171.9 | 96.5 | - | 165.6 | 113.1 | 125.9 | - | 145.3 | 140.4 | 120.1 | - | 123.8 | 124.4 | 123.1 | - | 121.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
57.3 | - | 82.1 | 86.4 | 83.9 | - | - | - | 155.9 | - | - | - | - | - | 49.3 | 69.5 | - | 55.8 | 52.5 | 28.1 | - | 82.4 | 57.8 | 56.3 | - | 68.4 | 66.1 | 54.1 | - | 52.8 | 53.0 | 48.8 | - | 44.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
291.1 | - | 212.8 | 205.5 | 197.1 | - | - | - | 452.8 | - | - | - | 62.1 | - | 143.1 | 248.1 | 51.4 | 234.8 | 218.8 | 117.0 | - | 219.0 | 163.4 | 174.2 | 48.5 | 197.7 | 193.0 | 167.8 | 43.1 | 169.4 | 171.7 | 172.0 | 52.0 | 177.4 | 56.2 | 51.1 | 48.8 | 53.4 | 53.7 | 46.0 | 41.3 | 44.6 | 41.6 | 20.1 | - | 47.0 | 48.4 | 49.2 | 47.1 | 51.0 | 51.0 | 48.5 | 45.2 | 50.2 | 50.5 | 47.8 | 46.3 | 50.0 | 47.5 | - |
Cash Conversion Cycle |
233.8 | - | 130.7 | 119.1 | 113.1 | - | - | - | 296.8 | - | - | - | 62.1 | - | 93.7 | 178.6 | 51.4 | 179.0 | 166.3 | 88.9 | - | 136.6 | 105.5 | 117.9 | 48.5 | 129.3 | 126.9 | 113.6 | 43.1 | 116.7 | 118.6 | 123.2 | 52.0 | 132.9 | 56.2 | 51.1 | 48.8 | 53.4 | 53.7 | 46.0 | 41.3 | 44.6 | 41.6 | 20.1 | - | 47.0 | 48.4 | 49.2 | 47.1 | 51.0 | 51.0 | 48.5 | 45.2 | 50.2 | 50.5 | 47.8 | 46.3 | 50.0 | 47.5 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Masimo Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
The Cooper Companies
COO
|
$ 60.79 | 0.68 % | $ 12.1 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
iRhythm Technologies
IRTC
|
$ 115.17 | 0.88 % | $ 3.69 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
ICU Medical
ICUI
|
$ 121.75 | -1.01 % | $ 3 B | ||
|
Repro Med Systems
KRMD
|
$ 3.89 | -2.26 % | $ 180 M | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Intuitive Surgical
ISRG
|
$ 426.62 | -0.34 % | $ 152 B | ||
|
LeMaitre Vascular
LMAT
|
$ 99.14 | -0.36 % | $ 2.24 B | ||
|
Alcon
ALC
|
$ 64.53 | 0.8 % | $ 40.4 B | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | ||
|
Envista Holdings Corporation
NVST
|
$ 23.88 | 0.13 % | $ 4.01 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
electroCore
ECOR
|
$ 6.3 | -2.02 % | $ 53.4 K | ||
|
Haemonetics Corporation
HAE
|
$ 56.86 | -0.4 % | $ 2.86 B | ||
|
STAAR Surgical Company
STAA
|
$ 31.88 | -0.42 % | $ 1.58 B | ||
|
STERIS plc
STE
|
$ 215.75 | -0.17 % | $ 21.3 B | ||
|
Teleflex Incorporated
TFX
|
$ 130.11 | -0.13 % | $ 5.81 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Glaukos Corporation
GKOS
|
$ 142.59 | 0.3 % | $ 6.91 B | ||
|
InfuSystem Holdings
INFU
|
$ 8.53 | -1.24 % | $ 176 M | ||
|
Microbot Medical
MBOT
|
$ 1.92 | 3.51 % | $ 87.9 M | ||
|
Milestone Scientific
MLSS
|
$ 0.34 | -0.15 % | $ 27.9 M | ||
|
Merit Medical Systems
MMSI
|
$ 62.51 | -0.08 % | $ 3.7 B | ||
|
Utah Medical Products
UTMD
|
$ 63.24 | -0.72 % | $ 205 M | ||
|
West Pharmaceutical Services
WST
|
$ 302.94 | 0.92 % | $ 21.9 B | ||
|
Pulse Biosciences
PLSE
|
$ 24.97 | -7.88 % | $ 1.68 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 10.04 | -3.6 % | $ 2 B | ||
|
Retractable Technologies
RVP
|
$ 0.69 | - | $ 20.7 M | ||
|
Pro-Dex
PDEX
|
$ 59.29 | 1.09 % | $ 195 M | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
BioLife Solutions
BLFS
|
$ 20.77 | -1.36 % | $ 992 M | ||
|
Stereotaxis
STXS
|
$ 1.88 | -3.34 % | $ 171 M | ||
|
Baxter International
BAX
|
$ 17.56 | -1.29 % | $ 9.01 B | ||
|
ResMed
RMD
|
$ 204.64 | 1.03 % | $ 29.9 B | ||
|
AtriCure
ATRC
|
$ 28.64 | 1.72 % | $ 1.37 B | ||
|
Harvard Bioscience
HBIO
|
$ 5.48 | -0.69 % | $ 243 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
AngioDynamics
ANGO
|
$ 11.01 | -0.18 % | $ 450 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 143.69 | -0.57 % | $ 41.3 B | ||
|
Nephros
NEPH
|
$ 3.21 | -3.94 % | $ 34.1 M | ||
|
OraSure Technologies
OSUR
|
$ 3.04 | 3.05 % | $ 223 M | ||
|
Repligen Corporation
RGEN
|
$ 105.54 | 2.09 % | $ 5.93 M |